Montreal, Quebec, Canada - June 26, 2012 (Investorideas.com Newswire) Sunshine Biopharma Inc. (OTCBB: SBFM),
a pharmaceutical company focused on the research, development and
commercialization of drugs for the treatment of various forms of cancer,
today announced that it has completed a cytotoxicity study of its lead
compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung
Cancer cell line. Cytotoxicity studies measure the ability of a drug to
destroy cancer cells in vitro. The results of the study showed that
Adva-27a is significantly more effective at killing Multidrug Resistant
Small Cell Lung Cancer cells than Etoposide, the current commonly used
drug for this type of cancer. This is the second form of Multidrug
Resistant Cancer that Adva-27a has shown effectiveness against. The
first, which we had announced on July 11, 2011, was MCF-7/MDR Multidrug
Resistant Breast Cancer.
"These findings are very interesting", said Dr. Steve N. Slilaty,
Sunshine’s President and CEO. "Cancer cells become resistant to
anti-tumour drugs by overproducing a certain type of trans-membrane
proteins called ABC Transporters. These trans-membrane proteins bind and
transport drugs from the intracellular milieu to the outside of cancer
cells thereby making them resistant. Of the approximately 49 ABC
Transporters identified to date, two are most often found in Multidrug
Resistant Cancer: MDR1 and MRP1. The MCF-7/MDR Multidrug Resistant
Breast Cancer cell line, which we had previously announced overproduces
MDR1 while the H69AR Multidrug Resistant Lung Cancer cell line test in
the present study overproduces MRP1. It is remarkable that our Adva-27a is able to overcome both of these resistance proteins", he added.
About Sunshine Biopharma Inc. (OTCBB: SBFM)
www.sunshinebiopharma.com
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not
strictly historical, including statements as to revenue projections,
business strategy, outlook, objectives, future milestones, plans,
intentions, goals, future financial
conditions, future collaboration agreements, the success of the
Company's development, events conditioned on stockholder or other
approval, or otherwise as to future events, such statements are
forward-looking, and are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements contained in this release are subject to
certain risks and uncertainties that could cause actual results to
differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Published at www.Investorideas.com Newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure :
The Investorideas.com is a third party publisher of news and research
Our sites do not make recommendations, but offer information portals to
research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy
or sell products or securities. This site is currently compensated by
featured companies, news submissions and online advertising. Disclosure:
A third party on behalf of SBFM compensates Investorideas.com for news
release publishing and distribution : one hundred thousand 144 shares
for three months starting June 26 th. BC Residents and Investor
Disclaimer : Effective September 15 2008 - all BC investors should
review all OTC and Pink sheet listed companies for adherence in new
disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
No comments:
Post a Comment